newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination